Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Fuji
US Department of Justice
Citi
Chubb
Cantor Fitzgerald
Farmers Insurance
McKinsey
Baxter
Daiichi Sankyo

Generated: August 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Pellet formulation for the treatment of the intestinal tract
Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Filing Date:Feb 07, 2003
Application Number:10/360,410
Claims:1. A process for preparing an orally administrable pharmaceutical pellet formulation having a controlled release profile for the treatment of the intestinal tract, which pellet comprises a core including an aminosalicyclic acid as a pharmaceutically active compound or a pharmaceutically acceptable salt thereof and optionally pharmaceutically tolerable additives, wherein the active compound is present in the core in a non gel-forming polymer matrix which matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluids and the active compound, the matrix-forming polymer making up at least 1% by weight of the total weight of the core, wherein the process comprises: mixing the active compound and the non gel-forming polymer matrix; scattering in a pharmaceutically tolerable additive; and extruding a moist mass of the matrix-forming polymer and the active compound.

2. The process of claim 1, wherein the matrix-forming polymer comprises co-poly(ethyl acrylate, methyl methacrylate) or ter-poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride).

3. The process of claim 1 or 2, wherein the matrix-forming polymer comprises 4 to 10% by weight of the total weight of the core.

4. The process of claim 1, wherein the aminosalicyclic acid comprises 5-aminosalicyclic acid.

5. The process of claim 1, further comprising applying an enteric coating to a pellet formed from the moist mass.

6. The process of claim 5, wherein the enteric coating comprises a methacrylic acid containing copolymer or methylhydroxypropyl cellulose phthalate.

7. The process of claim 6, wherein the methacrylic acid containing copolymer comprises co-poly(methacrylic acid, methyl methacrylate), wherein the co-polymer comprises free carboxylic acid functional groups.

8. A process for preparing an orally administrable pharmaceutical pellet formulation having a controlled release profile, which pellet comprises a core comprising 5-aminosalicylic acid (5-ASA) or a pharmaceutically acceptable salt thereof, wherein the 5-ASA is present in the core in a non gel-forming polymer matrix, wherein the matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluids, the process comprises: mixing the 5-ASA and the non gel-forming polymer matrix; scattering in magnesium sterate; and extruding a moist mass.

9. The process of claim 8, further comprising applying an enteric coating to a pellet formed from the moist mass.

10. The process of claim 9, wherein the enteric coating comprises a methacrylic acid containing copolymer or methylhydroxypropyl cellulose phthalate.

11. The process of claim 10, wherein the methacrylic acid containing copolymer comprises co-poly(methacrylic acid, methyl methacrylate), wherein the co-polymer comprises free carboxylic acid functional groups.

12. The process of claims 1 or 8, further comprising cutting the moist mass into pieces.

13. The process of claim 12, wherein the pieces are about 1 mm long.

14. The process of claim 12, further comprising rounding the pieces in a spheronizer.

15. The process of claim 14, further comprising drying the pieces.

16. The process of claim 15, wherein the pieced are dried at about 60.degree. C.

17. The process of claim 15, further comprising: dissolving poly(methacrylic acid, methylmethacrylate) 1:1 in an ethanol/water mixture; suspending triethyl citrate, talc, titanium dioxide and magnesium state in the mixture; and coating the pieces with the suspended mixture.

18. The process of any of claims 7, 8, 9, 10, or 11, further comprising applying a single coating layer to a pellet formed from the moist mass.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
US Army
Citi
Merck
McKinsey
Deloitte
Accenture
UBS
Cantor Fitzgerald
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot